# Carbylan Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/carbylan-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Palo Alto, US
- Website: www.carbylan.com
- Total disclosed funding: $28M
- Latest round: Series B (Nov 9, 2007)
- Investors on record: 3

## About

Carbylan Therapeutics, Inc. specializes in the development of innovative therapeutic solutions aimed at addressing specific healthcare challenges through advanced technology and effective treatment options.Carbylan Therapeutics, Inc. was founded in 2004 and is headquartered in Palo Alto, US. The company focuses on therapeutics for various medical conditions. In April 2015, the company raised USD 65 mn in an IPO, selling 13 million shares at USD 5 per share. Following this, in June 2016, it agreed to merge with KalVista Pharmaceuticals, Inc., a transaction completed on November 22, 2016. Carbylan will change its name to KalVista Pharmaceuticals, Inc.The company’s primary offerings include innovative therapeutic solutions designed to address specific healthcare challenges, focusing on enhancing patient outcomes and treatment effectiveness. Their flagship product integrates advanced technology to improve treatment protocols for various medical conditions. Carbylan Therapeutics serves a diverse client base, including healthcare providers and institutions primarily in North America and Europe, aiming to improve efficiency and effectiveness in patient care.For the year 2015, Carbylan Therapeutics reported a revenue of USD 29,000 with an EBITDA of USD -20,123,000, indicating operational challenges during that period.Moving forward, Carbylan Therapeutics intends to leverage the funds raised from its IPO to support the development of new therapeutic products targeted at specific medical conditions. The company aims to expand its market reach, particularly into Europe and Asia, by 2017. The recent funding will be utilized for research and development efforts as well as strategic marketing initiatives to enhance its product offerings in the evolving healthcare landscape.

## Funding rounds

- Series B, Nov 9, 2007, $20M — Alta Partners, InterWest Partners, Vivo Capital
- Series A, Jan 13, 2006, $7.8M — Alta Partners, InterWest Partners

## Investors

- Alta Partners (https://capitalatlas.ai/funds/alta-partners) — Series A, Series B
- InterWest Partners (https://capitalatlas.ai/funds/interwest-partners) — Series A, Series B
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series B